Slide 1: ASX Announcement: Investor presentation
ASX ANNOUNCEMENT 29 August 2022 Investor presentation For personal use only 29 August 2022 – Cann Group Limited (ASX: CAN) (Cann or the Company) is pleased to invite shareholders, investors and interested parties to an investor update webinar and Q&A with CEO Peter Crock, COO Shane Duncan and CFO De
Slide 2: FY22 full year results and business update
For personal use only FY22 full year results and business update August 2022 Cann Group Limited ABN 25 603 949 739
Slide 3: Disclaimer | Important notice
Disclaimer | Important notice This presentation (Presentation) has been prepared by Cann Group Limited (ABN 25 603 949 739) (Cann). For personal use only Summary information This Presentation contains summary information about Cann and its activities which is current as at the date of this Presentat
Slide 4: Agenda
Agenda Financial Results Enhancing patients’ lives by For personal use only 1 developing, producing and supplying innovative cannabis medicines. Commercial Operations 2 Mildura Update 3 Satipharm Update 4 Strategic Priorities 5 Outlook for FY23 6 Growth Pillars 7
Slide 5: Financial results
For personal use only 1 Financial results
Slide 6: Financial results
For personal use only Financial results FY22 FY21 Mvt % Mvt 000's 000's • Sales revenue was $6.4m representing an increase of Revenue from operating activities 6,411 4,293 2,118 49.3% 49% on the prior financial year. Other income 4,827 4,275 • R&D Tax Incentive refund of $1.8m accrued to March Opera
Slide 7: Commercial operations
For personal use only 2 Commercial operations
Slide 8: Commercial operations | Sales & supply
For personal use only Commercial operations | Sales & supply Domestic International (% split) (% split) • Sales increase 49% on prior year to $6.4m across 17 customers comprising white label, private label, API, Satipharm 38% 62% and Satipharm products. • Expanded Australian business development tea
Slide 9: GMP capabilities drive margin expansion
GMP capabilities drive margin expansion For personal use only • Mildura and Southern facilities issued with GMP licences. • Allows for manufacturing, which includes extraction, Satipharm capsules and dried flower products. • GMP-approved analytical chemistry lab can now conduct mandatory regulatory
Slide 10: Mildura facility
For personal use only 3 Mildura facility
Slide 11: Mildura facility
For personal use only Mildura facility • Construction and commissioning of major components complete. • ODC permits granted in March / April 2022. • GMP manufacturing licence granted in June 2022. • Satipharm CBD capsule production commenced. • Harvesting of first commercial crop in June 2022 follow
Slide 12: Mildura | Commissioned & operational
Mildura | For personal use only Commissioned & operational 11 |
Slide 13: Cann Group's broad suite of capabilities
For personal use only Cann Group’s broad suite of capabilities Large-scale, high-tech ODC and GMP Capsule manufacturing cultivation licensed High quality capability In-house analytical dried flower, APIs Proprietary high-yield Drug registration testing and extracts genetics program Cann is now able
Slide 14: Satipharm update
For personal use only 4 Satipharm update
Slide 15: Satipharm | registration trial underway & option signed on major distribution agreement
Satipharm | registration trial underway & option For personal use only signed on major distribution agreement Phase III registration trial underway to support S3 (pharmacy OTC) product approval in Australia. • Short-term treatment of sleep disturbances and quality of life outcomes. • Over 50% of par
Slide 16: Satipharm | Sales & marketing update
Satipharm | Sales & marketing update • UK Food Standards Agency (FSA) review process delays impacted numerous products, contracting the overall CBD market*, though For personal use only we are seeing signs of a strong recovery post April 2022. • FSA validated the sale of Satipharm products in April
Slide 17: Strategic priorities for FY23 and beyond
For personal use only 5 Strategic priorities for FY23 and beyond
Slide 18: Strategic priorities
For personal use only Strategic priorities Streamlining our Aiming to fully utilise Capitalising on Pivoting to a stronger operational base to commercial focus the Mildura facility and Satipharm CBD capsule secure greater capabilities S3 opportunity efficiencies • Accelerating sales • Review of manu
Slide 19: Outlook for FY23
For personal use only 6 Outlook for FY23
Slide 20: Outlook for FY23
Outlook for FY23 For personal use only • Cann Group has commenced the FY23 financial year with a clear focus on building sales revenue as quickly as possible. • Additional resources will be allocated to commercial activities, while the operational platform is streamlined to fully capitalise on Mildu
Slide 21: Pillars of growth
For personal use only 7 Pillars of growth
Slide 22: Pillars of growth
For personal use only Pillars of growth Capacity & Domestic & international Path to registered Innovative product capability business development products pipeline • Efficiently scalable to • Expanded domestic and • S3 registration program. • Accelerated plant meet growing demand. international cust
Slide 23: Contact
For personal use only Contact Peter Crock Chief Executive Officer peter.crock@canngrouplimited.com Deborah Ambrosini Chief Financial Officer deborah.ambrosini@canngrouplimited.com Rhys Cohen Senior Corporate Communications Manager rhys.cohen@canngrouplimited.com canngrouplimited.com | +61 3 9095 718